2,945 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Fielder Capital Group LLC

Fielder Capital Group LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 2,945 shares of the company’s stock, valued at approximately $480,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AMF Tjanstepension AB increased its position in Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares during the period. Howard Capital Management Group LLC boosted its stake in shares of Zoetis by 0.8% in the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock valued at $20,489,000 after purchasing an additional 883 shares during the last quarter. Strategic Blueprint LLC grew its position in shares of Zoetis by 2.4% during the 3rd quarter. Strategic Blueprint LLC now owns 3,016 shares of the company’s stock worth $589,000 after buying an additional 72 shares during the period. JFS Wealth Advisors LLC lifted its holdings in Zoetis by 217.2% in the third quarter. JFS Wealth Advisors LLC now owns 1,345 shares of the company’s stock valued at $263,000 after buying an additional 921 shares during the period. Finally, Oak Harvest Investment Services boosted its stake in Zoetis by 16.8% in the third quarter. Oak Harvest Investment Services now owns 11,685 shares of the company’s stock valued at $2,283,000 after acquiring an additional 1,681 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS stock opened at $164.95 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company’s 50 day moving average price is $166.25 and its two-hundred day moving average price is $177.49. The company has a market capitalization of $73.86 billion, a P/E ratio of 30.16, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. Zoetis’s dividend payout ratio is currently 36.56%.

Wall Street Analyst Weigh In

Several analysts have commented on ZTS shares. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $215.90.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.